CSPC Pharmaceutical (HKG:1093) obtained approval from China's National Medical Products Administration to conduct clinical trials of JMT106 in China, a Monday Hong Kong bourse filing said.

The indication for this clinical trial approval is advanced solid tumors.

Preclinical studies have shown a wide variety of indications with significant anti-tumor effects and a good safety profile in multiple malignant tumor models.